Jonathan P. Graham, Executive Vice President and General Counsel at Amgen Inc . (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $158 billion and "GOOD" financial ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Amgen Inc. sees the potential for 2025 revenues to top Wall Street estimates thanks to growth in cholesterol and cancer drugs ...

Shares of Amgen Inc. AMGN shed 1.42% to $293.54 Friday, on what proved to be an all-around dismal trading session for the ...

Research analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for Amgen in a research note issued to ...

Amgen Inc.'s ( NASDAQ:AMGN ) dividend will be increasing from last year's payment of the same period to $2.38 on 7th ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...

In this article, we are going to take a look at where Amgen Inc. (NASDAQ:AMGN) stands against other stocks that Jim Cramer discusses that are leading the Dow higher in 2025. On Thursday ...

Investment analysts at William Blair reduced their FY2025 earnings per share estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that ...